EUVIMEDEUVIMED entdecken
Crossref

Method Development of Pegmolesatide for Doping Analysis: A Novel Synthetic Erythropoietin‐Mimetic Agent

Lu Liu iD, Zhanliang Wang, Lingyu Zhao, Xinmiao Zhou iD, Lisi Zhang

Drug Testing and Analysis · 2025

DOI: 10.1002/dta.3931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Lu Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China. Hauptthemen laut MEDLINE: Doping in Sports, Substance Abuse Detection, Peptides, Erythropoietin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: General Administration of Sport of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pegmolesatide, a novel synthetic erythropoietin‐mimetic agent, was developed by the Hansoh Pharmaceutical Manufacturing Company Ltd. (Jiangsu, China). In late 2023, it was approved in China for the treatment of anemia in both dialysis and non‐dialysis patients with chronic kidney disease, with the advantages of reduced immunogenicity and extended duration of action. The aim of this study was to develop a strategy for detecting pegmolesatide in doping analysis. Here, we present a bottom‐up nano‐liquid chromatography–high‐resolution tandem mass spectrometry approach for qualitative analysis of pegmolesatide using erythropoietin receptor coupled magnetic beads, followed by trypsinization and subsequent detection of characteristic peptides. Using full scan and data‐dependent MS/MS (ddMS2) modes, two characteristic peptide segments of pegmolesatide were identified. An analytical method using product ion scan mode was developed to detect the identified characteristic peptides. Both peptide segments were analyzed for the initial testing procedure, whereas one characteristic peptide segment obtained from complete trypsinization was analyzed for the confirmation procedure. After full validation, the selectivity, reliability, limit of detection, limit of identification, carryover, and stability were evaluated. The results demonstrate that our developed method can be a fit‐for‐purpose analytical method for the antidoping of pegmolesatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Doping in SportsSubstance Abuse DetectionPeptidesErythropoietinHumansTandem Mass SpectrometryLimit of DetectionReproducibility of ResultsChromatography, Liquid

Stichwörter der Autor:innen

HRMSantidopingerythropoietin‐mimetic peptidepolyethylene glycol

Substanzen

PeptidesErythropoietin

Autor:innen und Institutionen

  • Beijing Anti-Doping Laboratory, Beijing Sport University, Beijing, China.

ORCID-Profile: Lu Liu, Xinmiao Zhou

Förderung

  • General Administration of Sport of China

Zitieren

APA

Liu, L., Wang, Z., Zhao, L., Zhou, X., & Zhang, L. (2025). Method Development of Pegmolesatide for Doping Analysis: A Novel Synthetic Erythropoietin‐Mimetic Agent. Drug Testing and Analysis. https://doi.org/10.1002/dta.3931

Vancouver

Liu L, Wang Z, Zhao L, Zhou X, Zhang L. Method Development of Pegmolesatide for Doping Analysis: A Novel Synthetic Erythropoietin‐Mimetic Agent. Drug Testing and Analysis. 2025. doi:10.1002/dta.3931

BibTeX
@article{Liu2025,
  author = {Liu, Lu and Wang, Zhanliang and Zhao, Lingyu and Zhou, Xinmiao and Zhang, Lisi},
  title = {Method Development of Pegmolesatide for Doping Analysis: A Novel Synthetic Erythropoietin‐Mimetic Agent},
  journal = {Drug Testing and Analysis},
  year = {2025},
  doi = {10.1002/dta.3931}
}
Kostenlos starten →